Pfizer Inc. (PFE) Enterprise Value (EV): $207.77B
The enterprise value (EV) for Pfizer Inc. (PFE) is $207.77B as of Wednesday, June 10, 2026.
PFE Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$207.77B
PFE Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Pfizer Inc. (PFE) | — | $207.77B |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | $199.07B |
| Gilead Sciences, Inc. (GILD) | $151.21B | $169.72B |
| Abbott Laboratories (ABT) | $154.66B | $225.43B |
| Danaher Corporation (DHR) | $130.25B | $175.72B |
| CVS Health Corporation (CVS) | $125.16B | $185.63B |
| Bristol-Myers Squibb Company (BMY) | $114.14B | $147.02B |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | $248.87B |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | $114.72B |
| Amgen Inc. (AMGN) | $183.75B | $221.57B |
Enterprise Value Calculation
Market Cap
$146.36B
Total Debt
$65.13B
Cash
$1.14B
Enterprise Value
$207.77B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Pfizer Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Pfizer Inc. (PFE)?
- The enterprise value (EV) for PFE stock is $207.77B.
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla